Bharat Edition

Bharatstox

← All stocks

Sigachi Industries Ltd.

NSE: SIGACHI · Healthcare

Sector

Healthcare

Size band

Small cap

Market cap

733cr

ROE

10.5%

Dividend yield

0.5%

No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.

Measured against

Operating margin13.6%
peer 21.0%
Revenue growth−5.4%
peer 16.4%
Sigachi Industries Ltd.peer median

Peer set

Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener
CompanyOperating marginRevenue growth
Sun Pharmaceutical Industries Ltd.29.0%10.5%
Divi's Laboratories Ltd.41.0%27.8%
Torrent Pharmaceuticals Ltd.34.0%54.8%
Lupin Ltd.30.0%32.1%
Dr. Reddy's Laboratories Ltd.11.0%−5.5%
Cipla Ltd.17.0%2.3%
Zydus Lifesciences Ltd.24.0%22.0%
Mankind Pharma Ltd.26.0%12.9%
Aurobindo Pharma Ltd.21.0%16.3%
Torrent Power Ltd.19.0%2.8%
Alkem Laboratories Ltd.20.0%10.9%
Sigachi Industries Ltd.13.6%−5.4%

What management said

8 statements on record

Earnings call · Q1 FY27 · 20 Aug 2026

  • Revenue→INR650 crores to INR675 crores· FY27
    “Yes, yes. There is no change in guidance.”
  • EBITDA margin→18%· FY27
    “Full year EBITDA we have expected is 18%.”
  • API revenue→more than INR100 crores to INR110 crores
    “we are expected to achieve more than INR100 crores to INR110 crores or even more than that also, but as of now, easily we can achieve.”
  • Cellulose-based excipient capacity→30,000 metric tons per annum· Q2 of FY28
    “12,000 metric ton per annum MCC capacity expansion at the Dahej-2 continues to progress on schedule and upon commissioning, which is targeted by Q2 of FY28 will take our total cellulose-based excipient capacity to 30,000 metric tons per annum.”
  • Croscarmellose Sodium capacity→1,800 ton
    “In parallel, our 1,800 ton Croscarmellose Sodium facility at Dahej SEZ continues to advance supporting our overall move of higher-value excipient categories and a stronger overall product mix.”
  • Capex→more than INR100 crores· FY27
    “FY27 around more than INR100 crores we are going to incur.”
  • Capex→INR150 crores to INR200 crores· FY28
    “And FY28, it would be another INR150 crores to INR200 crores would be there.”
  • Capacity utilisation→beyond 95%, 96%· year end
    “So, but definitely our run rate will be beyond 95%, 96% as we get closer to the year end.”

Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.

On air

1 call · outcomes not tracked

Recorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.

Channel & showAiredStated targetStated stopOutcome
CNBC AwaazCNBC Awaax · no registration attached26 Aug+22.3%-24.3%still open

Shareholding

change across 4 filings
CategoryJun 26Mar 26Dec 25Sep 25Change
Promoters36.736.739.740.5−3.8
Foreign institutions1.31.33.33.1−1.8
Domestic institutions0.00.00.00.00.0
Retail & others62.162.057.056.4+5.7

As filed with the exchange for the periods ending Sep 25 to Jun 26.

Filings

latest 25 of 211
  • Certificate under SEBI (Depositories and Participants) Regulations, 20187 Oct 2026
    RoutineGeneralFiling PDF ↗
  • Updates30 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Shareholders meeting30 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Shareholders meeting29 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Updates28 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Trading Window25 Sept 2026
    Medium impactInsider TradingFiling PDF ↗
  • Shareholders meeting16 Sept 2026
    RoutineGeneralFiling PDF ↗
  • EGM-Voting Results and Scrutinizers Report16 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Shareholders meeting15 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Outcome-Proceedings of EGM15 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Copy of Newspaper Publication11 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Newspaper Publication11 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Corrigendum to Notice of ExtraOrdinary General Meeting9 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Corrigendum9 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Copy of Newspaper Publication8 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Newspaper Publication8 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Company has fixed September 22, 2026 as record date for the purpose of Dividend for the financial year ended 31.03.20267 Sept 2026
    Medium impactDividendFiling PDF ↗
  • Record Date7 Sept 2026
    Medium impactDividendFiling PDF ↗
  • General Updates7 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Business Responsibility and Sustainabilty Report for FY 2025-267 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Shareholders meeting7 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Notice of 37th Annual General Meeting7 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Copy of Newspaper Publication25 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Newspaper Publication for Extra-Ordinary General Meeting25 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Shareholders meeting24 Aug 2026
    RoutineGeneralFiling PDF ↗

The 25 most recent of 211 filings we hold for SIGACHI, back to January 2024. Every filing, by day.

Disclaimer

Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.

Bharat ke stocks, har subah.

One daily brief on what India's SEBI-registered research analysts are calling. No noise, no spam, unsubscribe whenever.